|
Accueil > Actualité
Pfizer: encouraging data in breast cancer
(CercleFinance.com) - Pfizer and Arvinas today announced positive top-line results from a Phase 3 clinical trial evaluating vepdegestrant monotherapy versus fulvestrant in adults with estrogen receptor-positive and human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer.
The trial demonstrated a statistically and clinically significant improvement in progression-free survival (PFS) compared with fulvestrant. This data supports vepdegestrant's potential to give patients whose tumors harbor ESR1 mutations additional time without disease progression, compared with fulvestrant, Pfizer summarizes. Copyright (c) 2025 CercleFinance.com. All rights reserved. |
10/04/2025 18:30
Argansigne un bail BEFA pour un nouvel entrepôt 'Aut0nom' 10/04/2025 18:20 Eurazeoinvestit dans Ekoscan Integrity Group (EIG) 10/04/2025 18:10 Colascontrat de 100ME sur 7 ans pour la filiale canadienne 10/04/2025 16:50 GE HealthCarepartenariat avec Cincinnati Children's 10/04/2025 16:38 Fordle titre recule, Goldman Sachs passe à 'neutre' 10/04/2025 16:23 LNA SantéFlorac Investissements à plus de 5% des votes Tous les articles sociétés |
